Ultragenyx Pharmaceutical Inc.
RARE
$39.34
$0.090.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.42% | 42.27% | 35.75% | 8.30% | 23.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.42% | 42.27% | 35.75% | 8.30% | 23.27% |
| Cost of Revenue | 8.21% | 91.33% | 4.53% | 10.15% | 275.01% |
| Gross Profit | -3.15% | 36.07% | 46.27% | -12.56% | -632.50% |
| SG&A Expenses | 7.37% | 7.25% | -0.98% | 1.98% | 5.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.12% | 11.65% | 2.78% | 7.69% | 0.19% |
| Operating Income | -0.19% | 9.04% | 21.35% | -7.30% | 16.19% |
| Income Before Tax | -5.13% | 16.22% | 17.82% | -4.13% | 17.22% |
| Income Tax Expenses | 99.49% | -53.38% | 17.21% | -8.08% | -155.13% |
| Earnings from Continuing Operations | -8.28% | 16.37% | 17.66% | -4.09% | 18.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.28% | 16.37% | 17.66% | -4.09% | 18.86% |
| EBIT | -0.19% | 9.04% | 21.35% | -7.30% | 16.19% |
| EBITDA | 0.56% | 10.64% | 24.61% | -5.13% | 19.08% |
| EPS Basic | 8.20% | 37.24% | 32.58% | 13.09% | 29.83% |
| Normalized Basic EPS | 13.19% | 36.24% | 34.87% | 10.97% | 28.21% |
| EPS Diluted | 8.20% | 37.24% | 32.58% | 12.88% | 29.83% |
| Normalized Diluted EPS | 13.19% | 36.24% | 34.87% | 10.97% | 28.21% |
| Average Basic Shares Outstanding | 17.95% | 33.25% | 22.12% | 19.78% | 15.63% |
| Average Diluted Shares Outstanding | 17.95% | 33.25% | 22.12% | 19.78% | 15.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
